Detalhe da pesquisa
1.
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 73(4): 70, 2024 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38430375
2.
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(12): 1334-1348, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039991
3.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 21(12): 1574-1588, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32971005
4.
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
J Transl Med
; 17(1): 429, 2019 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31878938
5.
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Clin Cancer Res
; 29(11): 2066-2074, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36806911
6.
Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation.
Cancer Res Commun
; 2(1): 39-48, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36860696
7.
Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing.
Cancers (Basel)
; 13(6)2021 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33804698
8.
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
JAMA Oncol
; 5(2): 195-203, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30383184